Schrödinger, Inc. reports Q2 results on August 5 carrying one of the more charged short setups in health care technology — yet the options market is sending a notably different signal, leaving the pre-earnings picture genuinely split.
Short interest is the dominant story here. Bears hold 16.4% of the free float, a level that has crept higher by roughly 2% over the past week alone and is running near the top of its recent range. That is a meaningful short position by any standard, and the ORTEX short score of 70.9 — nudging higher through July — reflects the sustained bearish conviction. Days-to-cover from official FINRA data sits at 9.75, meaning any rapid price move would take shorts well over a week to unwind at normal trading volumes. The lending market, however, does not corroborate a squeeze setup: availability is comfortable at 240%, meaning roughly two-and-a-half shares are available to borrow for every one already lent out, well within the normal range. Cost to borrow is just 0.44% — eased about 8% on the week — flagging no stress in the borrow market. The short position is large, but the conditions for a mechanically forced unwind are absent.
Options traders are striking a calm tone heading into the print. The put/call ratio at 0.56 is marginally below its 20-day average of 0.57, with a z-score barely negative at -0.32 — essentially in line with recent norms. Notably, the PCR has drifted lower through July after spending mid-month closer to 0.60. That pattern suggests options participants have been reducing defensive positioning into the event, not adding to it, which is an unusual read given the heavy short interest in the stock.
The Street's consensus remains "buy," with a mean price target of $20.57 against the current $15.14 — implying roughly 36% upside. That framing needs context, though: the most recent analyst moves have been almost uniformly negative on targets. Morgan Stanley trimmed to $17 in May, Keybanc cut to $20 in April, and UBS moved to $13 in March. The direction of travel among analysts is clearly downward, even where ratings have stayed positive or neutral. Factor scores reinforce the caution: EPS momentum over 30 days ranks in just the 28th percentile, the analyst recommendation differential scores only at the 5th percentile, and the short score rank sits at the 5th percentile — among the most heavily shorted names in the universe on that measure. The one bright spot is EPS surprise, which ranks in the 83rd percentile, suggesting the company has beaten consensus estimates consistently even as those estimates keep falling.
The ownership picture is worth a brief note. The Bill & Melinda Gates Foundation Trust holds 21.6% of shares — a cornerstone position that has not changed recently and provides a floor of sorts to the register. ARK Investment Management added 73,399 shares in July, a modest incremental buy that at least signals continued conviction from one active growth manager. Insider activity tells a less flattering story: CEO Ramy Farid sold over $1 million of stock in April, and the CFO has made small but consistent disposals. Net insider activity over the prior 90 days shows net selling of roughly $539,000 in value.
The last two earnings reactions give a narrow but useful frame. The most recent print in June produced a 4.6% one-day drop, though the stock recovered fully within a week to close the five-day window up 10.3%. The May print saw a modest gain on the day but faded slightly over the following week. Neither reaction was dramatic, and with availability well-supplied and borrow cheap, there is no mechanical short-covering pressure that would amplify the move in either direction. The August 5 print is therefore less about whether bulls or bears are right on valuation and more about whether the latest results shift the narrative on revenue growth — the metric that has been doing the most work in determining which direction the 16%-short float resolves.
See the live data behind this article on ORTEX.
Open SDGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
SDGR reports Q1 2026 results today with one of the more interesting short-side setups in health care technology — a heavily shorted name where the bears have quietly been retreating. Short interest remains substantial…
